Natalie E Izaguirre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Natalie E Izaguirre has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Lindsey R Baden
Harvard Medical School , Boston, Massachusetts, USA
2 shared publications- Alexandra Morgan
Department of Pathology, Beth Israel Deaconess Medical Center (BIDMC), Boston, MA 02215, USA
1 shared publication - Alexandra Tong
Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts
1 shared publication - Amy Caryn Sherman
Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts
1 shared publication Andy J Kim
Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts, USA
1 shared publicationAnn E Woolley
Harvard Medical School , Boston, Massachusetts, USA
1 shared publication
Latest Publications
- 28 January 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (5) , 987-994
Comparative Outcomes of Babesiosis in Immunocompromised and Nonimmunocompromised Hosts: A Multicenter Cohort Study
Background: Babesiosis poses significant risks of adverse outcomes in individuals with immunocompromising conditions (IC) and asplenia/hyposplenia (AH). This study compares clinical outcomes between these vulnerable groups and immunocompetent patients. Methods: This multicenter retrospective cohort study included adult patients with laboratory-confirmed babesiosis from 2009 to 2023. Complications, management, and outcomes were compared between patients with IC/AH (ICAH) and without ICAH (immune intact cohort). Results: Of 225 patients (mean age 66 years, 36% female), 112 were ICAH. ICAH patients had higher median peak parasitemia (2.8% vs 0.9%, P < .0001) and higher rates of complications, including acute kidney injury (24% vs 11%, P = .016) and acute respiratory distress syndrome (11% vs 4%, P = .041), and were more likely to undergo packed red blood cell transfusion (31% vs 17%, P = .023) and exchange transfusion (18% vs 6%, P = .008). Treatment duration was longer in the ICAH cohort (median 27 vs 10 days, P < .001), particularly in those with both IC and AH (median 43 days, P = .003). ICAH patients had higher 12-month all-cause mortality (7% vs 1%, P = .019) and recurrence rates (8% vs 0%, P = .001). Hematologic malignancy (odds ratio = 7.0, P = .023) and B-cell–depleting therapies (odds ratio = 9.4, P = .015) were significant predictors of recurrence. Despite most patients undergoing follow-up testing with blood smears and polymerase chain reaction, these did not reliably predict recurrence. Conclusions: Patients with ICAH with babesiosis experience more severe disease and higher complication rates. Follow-up testing, including blood smear and polymerase chain reaction, did not reliably predict recurrence, highlighting the need for more effective monitoring strategies in these high-risk populations.
- 28 January 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (5) , 987-994
Comparative Outcomes of Babesiosis in Immunocompromised and Nonimmunocompromised Hosts: A Multicenter Cohort Study
Background: Babesiosis poses significant risks of adverse outcomes in individuals with immunocompromising conditions (IC) and asplenia/hyposplenia (AH). This study compares clinical outcomes between these vulnerable groups and immunocompetent patients. Methods: This multicenter retrospective cohort study included adult patients with laboratory-confirmed babesiosis from 2009 to 2023. Complications, management, and outcomes were compared between patients with IC/AH (ICAH) and without ICAH (immune intact cohort). Results: Of 225 patients (mean age 66 years, 36% female), 112 were ICAH. ICAH patients had higher median peak parasitemia (2.8% vs 0.9%, P < .0001) and higher rates of complications, including acute kidney injury (24% vs 11%, P = .016) and acute respiratory distress syndrome (11% vs 4%, P = .041), and were more likely to undergo packed red blood cell transfusion (31% vs 17%, P = .023) and exchange transfusion (18% vs 6%, P = .008). Treatment duration was longer in the ICAH cohort (median 27 vs 10 days, P < .001), particularly in those with both IC and AH (median 43 days, P = .003). ICAH patients had higher 12-month all-cause mortality (7% vs 1%, P = .019) and recurrence rates (8% vs 0%, P = .001). Hematologic malignancy (odds ratio = 7.0, P = .023) and B-cell–depleting therapies (odds ratio = 9.4, P = .015) were significant predictors of recurrence. Despite most patients undergoing follow-up testing with blood smears and polymerase chain reaction, these did not reliably predict recurrence. Conclusions: Patients with ICAH with babesiosis experience more severe disease and higher complication rates. Follow-up testing, including blood smear and polymerase chain reaction, did not reliably predict recurrence, highlighting the need for more effective monitoring strategies in these high-risk populations.
- Open Access
- 1 October 2020
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 7 (Supplement) , S42
36. Safety and Reactogenicity of the Adjuvanted Recombinant Zoster Vaccine after Allogeneic Hematopoietic Stem Cell Transplantation
Herpes zoster (HZ) is common after allogeneic hematopoietic stem cell transplantation (HCT) and associated with high morbidity. While antiviral prophylaxis reduces incidence, increased risk remains after discontinuation and vaccination strategies are needed. A non-live adjuvanted recombinant zoster vaccine (RZV) has been developed but not yet studied in this population. In this single center prospective observational cohort study, allogeneic HCT recipients ³18 years old and 9–24 months from HCT were eligible to receive 2 doses of RZV separated by ³8 weeks as part of revised institutional vaccination guidelines. The primary endpoint was safety and reactogenicity in the total vaccinated cohort (TVC). The secondary endpoints were incidence and severity of chronic graft versus host disease (cGVHD) in the TVC compared to historical controls and incidence rates of HZ in the TVC and modified total vaccinated cohort (mTVC). Of the 158 participants (mean age 55 years, 91 [58%] male) in the TVC, 150 (95%) received second vaccine. 92.1% had solicited reactions with 87.3% injection site reactions (18.7% grade 3) and 82.8% general reactions (26.5% grade 3). In the subgroup receiving first vaccine at 9–12 months after HCT, cumulative incidence of cGVHD was similar to historical controls at predefined time points between 9–15 months (unadjusted incidence rate ratio [IRR] 1.1 [95% CI 0.84–1.44], adjusted IRR 1.05 [95% CI 0.8–1.38]); there was also no difference in severity of cGVHD, or incidence of death or disease relapse. There were 4 (2.5%) HZ cases during the study period with IR 28.34/1000 person-years over median follow up 281 days (IQR 190, 354) in the mTVC. All cases occurred after antiviral prophylaxis discontinuation and one case resulted in death. Two doses of RZV after allogeneic HCT was safe and acceptable despite high rates of reactogenicity. There was no evidence of an increase in cGVHD, relapse, or death compared to historical controls and overall low rates of breakthrough HZ similar to those reported after autologous HCT. Immunogenicity studies and placebo-controlled trials are needed to determine vaccine response and efficacy so that timing of RZV and its potential impact on discontinuation of antiviral prophylaxis can be determined. Nicolas C. Issa, MD, AiCuris (Scientific Research Study Investigator)Astellas (Scientific Research Study Investigator)GSK (Scientific Research Study Investigator)Merck (Scientific Research Study Investigator)
- 1 October 2020
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 7 (Supplement) , S42
Open Access36. Safety and Reactogenicity of the Adjuvanted Recombinant Zoster Vaccine after Allogeneic Hematopoietic Stem Cell Transplantation
Herpes zoster (HZ) is common after allogeneic hematopoietic stem cell transplantation (HCT) and associated with high morbidity. While antiviral prophylaxis reduces incidence, increased risk remains after discontinuation and vaccination strategies are needed. A non-live adjuvanted recombinant zoster vaccine (RZV) has been developed but not yet studied in this population. In this single center prospective observational cohort study, allogeneic HCT recipients ³18 years old and 9–24 months from HCT were eligible to receive 2 doses of RZV separated by ³8 weeks as part of revised institutional vaccination guidelines. The primary endpoint was safety and reactogenicity in the total vaccinated cohort (TVC). The secondary endpoints were incidence and severity of chronic graft versus host disease (cGVHD) in the TVC compared to historical controls and incidence rates of HZ in the TVC and modified total vaccinated cohort (mTVC). Of the 158 participants (mean age 55 years, 91 [58%] male) in the TVC, 150 (95%) received second vaccine. 92.1% had solicited reactions with 87.3% injection site reactions (18.7% grade 3) and 82.8% general reactions (26.5% grade 3). In the subgroup receiving first vaccine at 9–12 months after HCT, cumulative incidence of cGVHD was similar to historical controls at predefined time points between 9–15 months (unadjusted incidence rate ratio [IRR] 1.1 [95% CI 0.84–1.44], adjusted IRR 1.05 [95% CI 0.8–1.38]); there was also no difference in severity of cGVHD, or incidence of death or disease relapse. There were 4 (2.5%) HZ cases during the study period with IR 28.34/1000 person-years over median follow up 281 days (IQR 190, 354) in the mTVC. All cases occurred after antiviral prophylaxis discontinuation and one case resulted in death. Two doses of RZV after allogeneic HCT was safe and acceptable despite high rates of reactogenicity. There was no evidence of an increase in cGVHD, relapse, or death compared to historical controls and overall low rates of breakthrough HZ similar to those reported after autologous HCT. Immunogenicity studies and placebo-controlled trials are needed to determine vaccine response and efficacy so that timing of RZV and its potential impact on discontinuation of antiviral prophylaxis can be determined. Nicolas C. Issa, MD, AiCuris (Scientific Research Study Investigator)Astellas (Scientific Research Study Investigator)GSK (Scientific Research Study Investigator)Merck (Scientific Research Study Investigator)